This is a summary of the European public assessment report (EPAR) for Aerinaze. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aerinaze.
Therapeutic Indication
### Therapeutic indication Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion.
Therapeutic Area (MeSH)
ATC Code
R01BA52
ATC Item
pseudoephedrine, combinations
Pharmacotherapeutic Group
Nasal preparations
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| desloratadine | N/A | 地氯雷他定 |
| pseudophedrine sulfate | N/A | pseudophedrine sulfate |
EMA Name
Aerinaze
Medicine Name
Aerinaze
Aliases
N/ANo risk management plan link.
